Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Apyx Medical Corp has a consensus price target of $8.88 based on the ratings of 6 analysts. The high is $17 issued by Lake Street on July 19, 2022. The low is $4.5 issued by Piper Sandler on August 11, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Piper Sandler, and Stephens & Co. on November 10, 2023, August 11, 2023, and July 14, 2023, respectively. With an average price target of $5.83 between Stephens & Co., Piper Sandler, and Stephens & Co., there's an implied 271.55% upside for Apyx Medical Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Apyx Medical (NASDAQ:APYX) was reported by BTIG on October 17, 2024. The analyst firm set a price target for $0.00 expecting APYX to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Apyx Medical (NASDAQ:APYX) was provided by BTIG, and Apyx Medical initiated their neutral rating.
There is no last upgrade for Apyx Medical
There is no last downgrade for Apyx Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apyx Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apyx Medical was filed on October 17, 2024 so you should expect the next rating to be made available sometime around October 17, 2025.
While ratings are subjective and will change, the latest Apyx Medical (APYX) rating was a initiated with a price target of $0.00 to $0.00. The current price Apyx Medical (APYX) is trading at is $1.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.